Cost-effectiveness of maternal pertussis immunization: Implications of a dynamic transmission model for low- and middle-income countries

Kim, Sun‐Young; Min, Kyung‐Duk; Jung, Sung-mok; Russell, Louise B.; Toscano, Cristiana M.; Minamisava, Ruth; Andrade, Ana Lúcia; Sanderson, Colin; Sinha, Anushua

doi:10.1016/j.vaccine.2020.09.012

Cited by 8 publications

(4 citation statements)

References 15 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional information is available in Supplementary Table 1 (see the electronic supplementary material). All eight included studies measured the DALYs of pregnant women and children separately [ 65 , 110 – 116 ]. Two studies considered the value of fetal loss in their analysis [ 112 , 113 ].…”

Section: Resultsmentioning

confidence: 99%

“…Subsequently, the combined incremental DALYs averted of pregnant women and children were estimated at the family level. In terms of reporting, three studies reported combined DALYs averted and incremental DALYs averted for pregnant women and children at the family level [ 110 , 111 , 115 ], while five studies reported separate DALYs averted and incremental DALYs averted, as well as combined DALYs averted and incremental DALYs averted at the family level [ 65 , 112 – 114 , 116 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses

Lamsal,

Yeh,

Pullenayegum

et al. 2024

PharmacoEconomics

View full text Add to dashboard Cite

Background Maternal-perinatal interventions delivered during pregnancy or childbirth have unique characteristics that impact the health-related quality of life (HRQoL) of the mother, fetus, and newborn child. However, maternal-perinatal cost-utility analyses (CUAs) often only consider either maternal or child health outcomes. Challenges include, but are not limited to, measuring fetal, newborn, and infant health outcomes, and assessing their impact on maternal HRQoL. It is also important to recognize the impact of maternal-perinatal health on family members’ HRQoL (i.e., family spillover effects) and to incorporate these effects in maternal-perinatal CUAs. Objective The aim was to systematically review the methods used to include health outcomes of pregnant women, fetuses, and children and to incorporate family spillover effects in maternal-perinatal CUAs. Methods A literature search was conducted in Medline, Embase, EconLit, Cochrane Collection, Cumulative Index to Nursing and Allied Health Literature (CINAHL), International Network of Agencies for Health Technology Assessment (INAHTA), and the Pediatric Economic Database Evaluation (PEDE) databases from inception to 2020 to identify maternal-perinatal CUAs that included health outcomes for pregnant women, fetuses, and/or children. The search was updated to December 2022 using PEDE. Data describing how the health outcomes of mothers, fetuses, and children were measured, incorporated, and reported along with the data on family spillover effects were extracted. Results Out of 174 maternal-perinatal CUAs identified, 62 considered the health outcomes of pregnant women, and children. Among the 54 quality-adjusted life year (QALY)-based CUAs, 12 included fetal health outcomes, the impact of fetal loss on mothers’ HRQoL, and the impact of neonatal demise on mothers’ HRQoL. Four studies considered fetal health outcomes and the effects of fetal loss on mothers’ HRQoL. One study included fetal health outcomes and the impact of neonatal demise on maternal HRQoL. Furthermore, six studies considered the impact of neonatal demise on maternal HRQoL, while four included fetal health outcomes. One study included the impact of fetal loss on maternal HRQoL. The remaining 26 only included the health outcomes of pregnant women and children. Among the eight disability-adjusted life year (DALY)-based CUAs, two measured fetal health outcomes. Out of 174 studies, only one study included family spillover effects. The most common measurement approach was to measure the health outcomes of pregnant women and children separately. Various approaches were used to assess fetal losses in terms of QALYs or DALYs and their impact on HRQoL of mothers. The most common integration approach was to sum the QALYs or DALYs for pregnant women and children. Most studies reported combined QALYs and incremental QALYs, or DALYs and incremental DALYs, at the family level for pregnant women and children. ...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses

Lamsal,

Yeh,

Pullenayegum

et al. 2024

PharmacoEconomics

View full text Add to dashboard Cite

show abstract

“…Duration of immunity is key to establishing optimal vaccination strategies and one of the parameters to which dynamic models of pertussis are most sensitive. Models have used values varying from 10 to 75 years to represent the duration of immunity from wP 46 . This wide range of assumptions clearly show a lack of consensus with regards to this estimate, likely resulting from a lack of good evidence in the literature.…”

Section: Discussionmentioning

confidence: 99%

Systematic review of immunogenicity and duration of immunity of currently licensed pertussis wP vaccines in children

et al. 2022

View full text Add to dashboard Cite

Background: Currently recommended whole cell pertussis (wP) vaccination schedule for children includes a 3-dose primary schedule, and at least one booster dose. When estimating the impact of additional strategies to reduce pertussis burden through modelling, duration of immunity conferred by childhood immunization is among the parameters models are most sensitive to. We aim to assess the duration of immunity of currently available wP vaccines in children and the additional protection conferred by booster doses. Methods: We conducted a systematic review of published studies of current commercially available vaccines indexed in Medline, Embase, Web of Science, Lilacs, SciELO and Central until September 2021. We included clinical trials, observational longitudinal, and cross-sectional studies. Citation screening, data extraction, and risk of bias and methodological quality assessment were done in duplicate by independent reviewers, following the study protocol registered in PROSPERO. Studies were included if they reported primary data on the protection, immunity, or duration of immunity conferred by ≥3 doses of wP vaccine in healthy children, without restriction to time or location of the study. Outcomes included clinical events or serological evidence of protection. Results: We included 12 studies conducted from 2007-2020 with heterogeneous methodological quality. Studies report on 5 of the 18 currently available wP vaccines in use. After primary immunization, geometric mean concentration (GMC) of anti-pertussis toxin ranged from 9.1 EU/mL (95% confidence intervals [CI]: 8.1-10.2) to 50.9 (95%CI: 45.9-56.4). Prior to the 1st booster, GMC titers were low ranging from 4.7 to 10 EU/mL, and after the 1st booster averaged around 42 EU/mL. Conclusions: The limited available evidence on immunogenicity of currently available wP vaccines reinforces the need for booster doses and suggests that the duration of wP immunity is short, probably <5 years. This is important information for vaccination policy makers, investigators and modelers. PROSPERO registration: CRD42018107309

show abstract

“…In wealthy nations, most hospitalizations for pertussis are for young babies, and the number of cases in this age group is on the rise (10). To assess if the findings from developed nations accurately represent the situation in Egypt and to determine if pertussis remains a concern in a population vaccinated solely with a whole-cell vaccine, it is necessary to understand the immunity levels within different populations.…”

Section: Introductionmentioning

confidence: 99%

Evaluating Pertussis Immunity in School-Aged Children Post DPT Vaccination

2023

jjoas-n

View full text Add to dashboard Cite

Background: Pertussis, also known as whooping cough, is a contagious disease that vaccines can prevent. In developed nations with high vaccination rates, pertussis has been resurgent despite the use of acellular vaccines. However, there is a need to assess pertussis immunity in developing countries that still rely on whole-cell vaccines. Aims: The present study was designed to evaluate the level of immunity of school-age children against pertussis after routine DPT vaccinations according to the Egyptian vaccination program. Methods: A cross-sectional descriptive study included 281 school-age children aged between 6 and 12 years who were free from acute or chronic illnesses and had average growth. Pertussis IgG testing was conducted for each child using the ELISA technique. Results: The study found that 51.9% of the children had a positive seroprevalence to pertussis, while 26% tested negative for seroimmunity and 22.1% had equivocal results. There was no relationship between the children's age and the pertussis seroprevalence. However, the urban population and those with a higher social status showed a higher frequency of negative seroprevalence to pertussis. Conclusion: Only 51.9% of school-age children showed positive seroprevalence to pertussis, potentially leaving many children unprotected against the infection. The level of pertussis IgG was not found to be correlated with the children's age or the duration of vaccination. Further large-scale studies are required to confirm these results and explore the status of pertussis infection in susceptible patients.

show abstract

Cost-effectiveness of maternal pertussis immunization: Implications of a dynamic transmission model for low- and middle-income countries

Cited by 8 publications

References 15 publications

A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses

A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses

Systematic review of immunogenicity and duration of immunity of currently licensed pertussis wP vaccines in children

Evaluating Pertussis Immunity in School-Aged Children Post DPT Vaccination

Contact Info

Product

Resources

About